Arsanis, Inc.
16 Cavendish Court
Lebanon
New Hampshire
03766
United States
Tel: 603-727-7107
Website: http://www.arsanis.com/
36 articles about Arsanis, Inc.
-
X4 Pharmaceuticals Completes Merger with Arsanis
3/13/2019
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR, as of March 14, 2019), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the completion of its merger with Arsanis, Inc. (Nasdaq: ASNS, through March 13, 2019), effective as of March 13, 2019.
-
Shares of Arsanis, Inc. stock are up more than 25 percent in premarket trading after the company announced that it will merge with privately-held X4 Pharmaceuticals, Inc. as part of a reverse merger that will provide X4 with a quick path to being traded on the Nasdaq.
-
Arsanis Provides Update Following Completion of Planned Interim Analysis of Phase 2 Clinical Tria...
6/28/2018
Arsanis, Inc. (NASDAQ:ASNS), today announced the discontinuation of its Phase 2 clinical trial of ASN100. -
Arsanis Reports Business Highlights and Financial Results for First Quarter 2018
5/10/2018
ASN100 Phase 2 Trial Interim Analysis Results Expected in Late June
-
Arsanis to Present at the 28th European Congress of Clinical Microbiology and Infectious Diseases
4/17/2018
Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases, announced today that the company will present five scientific posters at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Madrid, Spain from April 21 – 24, 2018
-
Shares of Arsanis, Inc. are inching up this afternoon following the company’s announcement of a licensing deal with Austria-based BB100, LLC, a subsidiary of Bravos Biosciences.
-
Arsanis Out-Licenses Preclinical Stage E. coli Monoclonal Antibodies
4/4/2018
Transaction provides potential for further development of novel mAbs while allowing Arsanis to continue to focus its resources on ongoing Phase 2 clinical trial of lead product candidate ASN100
-
Arsanis Granted Key Patents for ASN100 Covering Cross-Neutralizing S. aureus Toxin Antibodies
3/14/2018
Patents strengthen Company’s intellectual property portfolio for its lead product candidate ASN100 which is designed to uniquely address Staphylococcus aureus infections
-
Arsanis Reports Financial Results and Highlights for Fourth Quarter and Full Year 2017
3/9/2018
Commenced Phase 2 trial of lead program ASN100.
-
The 2017 Biotech IPO Winners and Losers
12/21/2017
Although it was an average year for mergers and acquisitions in the biopharma industry, it was a stronger year for IPOs. -
Arsanis Announces Closing of Initial Public Offering
11/20/2017
The gross proceeds to Arsanis from the offering were $46.0 million, before deducting underwriting discounts and commissions and other offering expenses.
-
Massachusetts' Arsanis Prices $40M in IPO
11/16/2017
The gross proceeds to Arsanis from the offering are expected to be $40.0 million, before deducting underwriting discounts and commissions and other offering expenses.
-
Arsanis Presents Phase I And Preclinical Pharmacokinetic Data On Lead Product Candidate, ASN100, At IDWeek 2017
10/9/2017
-
Arsanis Announces Appointments Of Chip Clark And David Mcgirr To Board Of Directors And Promotion Of Michael Gray To Chief Operating Officer And Chief Financial Officer
10/4/2017
-
Arsanis Presents Preclinical Data On Lead Product Candidate, ASN100, At The “2017 ASM/ESCMID Conference On Drug Development To Meet The Challenge Of Antimicrobial Resistance”
9/8/2017
-
Arsanis Scores $45.5 Million to Advance Infectious Disease Pipeline
4/26/2017
-
Arsanis And Adimab LLC. Enter Into License Agreement To Target Respiratory Syncytial Virus (RSV) With Monoclonal Antibodies
2/27/2017
-
Arsanis Release: Biopharma Announces First Patient Dosed In Global Phase 2 Study Of ASN100 For Prevention Of Staphylococcus Aureus Pneumonia
1/24/2017
-
Arsanis Receives FDA Fast Track Designation For ASN100 For The Prevention Of Staphylococcus Aureus Pneumonia
12/1/2016
-
Arsanis Announces Two Key Publications Supporting Its Lead Program ASN100
9/6/2016